Recently, inhibition of PD-1/PD-L1 with therapeutic antibodies showed broad efficacy in several cancers such as advanced melanoma, non-small lung cancer, colorectal cancer, and renal cell carcinoma [3,4]. Here, CD274 is linked to colorectal cancer.